Chemyo retatrutide searches are common, but Chemyo does not list retatrutide for sale. Learn the real status, testing standards, and what to check first.
Chemyo does not currently list retatrutide for sale in its public catalog, and retatrutide is not approved by the FDA for human use in the United States. Retatrutide is an investigational triple-agonist compound being developed by Eli Lilly, so any storefront that claims to sell it is selling an unapproved research chemical of unverified purity. If you landed here after searching for chemyo retatrutide, the honest answer is that Chemyo's catalog centers on other research compounds.
What Chemyo Sells Instead
Chemyo is a US-based research chemical vendor whose products carry the standard not-for-human-consumption label. At the time of writing, the catalog centers on:
- SARMs such as ostarine, RAD-140, LGD-4033, and cardarine
- Nootropic and ancillary research compounds
- A limited selection of peptides and liquid research solutions
Retatrutide is not part of that lineup. If Chemyo or any other vendor adds it later, the listing should ship with a batch-specific certificate of analysis (COA) that includes an HPLC purity trace and a mass spectrometry identity confirmation. A COA without a batch number is basically a marketing document.
What Is Retatrutide?
Retatrutide (development code LY3437943) is a single peptide that activates three hormone receptors at once: GLP-1, GIP, and glucagon. That triple mechanism is what separates it from earlier weight-management drugs, and it is the main reason interest in the compound is so high.
In a phase 2 trial published in 2023, participants on the highest dose lost an average of roughly 24% of their body weight over 48 weeks. Those results are promising, but they come from a controlled research setting, not from real-world use.
Retatrutide remains investigational in the United States. It has no FDA approval, no legal prescription pathway, and no pharmacy supply. Everything sold online today as retatrutide is therefore either a research-grade chemical or something else entirely.
How Retatrutide Compares to Other Compounds
| Compound | Receptors targeted | US status |
|---|---|---|
| Semaglutide | GLP-1 | FDA-approved |
| Tirzepatide | GLP-1 + GIP | FDA-approved |
| Cagrilintide | Amylin analog (studied with semaglutide) | Investigational |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational |
People comparing cagrilintide vs retatrutide vs tirzepatide are usually weighing mechanism and approval status rather than price. Tirzepatide is the only approved dual agonist in that group, cagrilintide is an amylin analog typically studied alongside semaglutide, and retatrutide is the furthest from market of the three.
What to Verify Before Trusting Any Retatrutide Listing
Unapproved peptides attract low-quality sellers, so verification matters more than branding. Use the checklist below on any vendor, including Chemyo if the product ever appears.
| Verification step | What good looks like | Red flag |
|---|---|---|
| Third-party testing | Independent lab COA with HPLC and mass spec data | In-house certificate with no lab name |
| Batch matching | Lot number on the vial matches the COA | One COA recycled across every product |
| Business transparency | Real address, responsive support, refund policy | Crypto-only checkout and no contact details |
| Shipping standards | Sealed vials, insulated packaging, tracking | Unlabeled powder in a baggie |
Dosage and Side Effects Reported in Trials
In published trials, retatrutide dosage has ranged from roughly 1 mg to 12 mg given as a once-weekly subcutaneous injection, with researchers titrating upward slowly to limit gastrointestinal reactions. Those numbers come from supervised clinical protocols and should not be read as a self-administration guide.
Reported retatrutide side effects in trials have been similar to those of other incretin-based drugs, and most were mild to moderate:
- Nausea, vomiting, and diarrhea
- Constipation and reduced appetite
- Injection-site reactions
- Increased resting heart rate
- Less common but serious: gallbladder disease and pancreatitis
Anyone considering a GLP-1-class compound should speak with a licensed healthcare professional first, particularly with a history of thyroid, pancreatic, or gallbladder problems.
Legal Status and Availability Timeline
The short answer to when will retatrutide be available is: not yet, and likely not before 2027 or 2028 if the phase 3 program succeeds. Eli Lilly has signaled that it intends to pursue regulatory approval, but no approval has been granted in the US or anywhere else as of this writing.
Searches for where to buy retatrutide mostly lead to gray-market peptide sellers, unregulated research chemical sites, and outright scams. Buying an unapproved injectable from an unverified source carries real risk: wrong identity, wrong concentration, bacterial contamination, and no recourse if something goes wrong.
A Practical Takeaway
If you want a compound that is legally available and clinically supervised, the approved GLP-1 and GIP/GLP-1 medications are the realistic path, obtained through a physician. If you are a researcher working with reference materials, buy only from vendors that publish batch-specific third-party testing and clearly state their products are not for human use.
Chemyo retatrutide is not a real product pairing today. Treat any page that claims otherwise as a reason to slow down and verify before spending money.
Frequently Asked Questions
Does Chemyo sell retatrutide?
At the time of writing, Chemyo's public catalog does not include retatrutide. The company lists SARMs, nootropics, and a small selection of peptides, all labeled not for human consumption. If you see a listing claiming otherwise, confirm it directly with the vendor before paying.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational drug and is not approved by the FDA for any human use, so it cannot be legally prescribed or dispensed by a US pharmacy. It is still being evaluated in phase 3 clinical trials.
When will retatrutide be available in the US?
If the phase 3 trials succeed and Eli Lilly files for approval, the earliest realistic US launch would be around 2027 to 2028. No launch date has been confirmed, and regulatory timelines often shift.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.